Concepedia

Author

Ewa Mędraś

Wroclaw Medical University

Also Known As

Ewa Medras, Ewa Mędraś

16

Publications

480

Citations

7

H-Index

13

Concepts

All Affiliations

Wroclaw Medical UniversityMedical University of SilesiaSarah CannonJena University HospitalThe Catholic University of Korea Seoul St. Mary's Hospital
EM

About

Ewa Mędraś is an author at Wroclaw Medical University specializing in radiation oncology, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

3

3

66

2

Medicine

3

3

66

3

Hematology

3

3

66

4

Pathology

1

1

40

5

Cancer Research

1

1

40

Ewa Mędraś

×

5

Publications

425

Citations

5

H-Index

YearCitations

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson,

Leukemia

2021

332

Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment

Joanna Góra‐Tybor, Ewa Mędraś, Małgorzata Całbecka,

Leukemia & lymphoma/Leukemia and lymphoma

2015

40

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, Giuseppe Saglio, Richard A. Larson,

Blood

2019

27

Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study

Tomasz Sacha, Joanna Góra‐Tybor, Ewa Wąsak-Szulkowska,

Clinical Lymphoma Myeloma & Leukemia

2017

15

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson,

Leukemia

2021

11

Page 1